GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Johnson & Johnson (NYSE:JNJ) » Definitions » Cyclically Adjusted PB Ratio

JNJ (Johnson & Johnson) Cyclically Adjusted PB Ratio : 4.86 (As of Jun. 30, 2025)


View and export this data going back to 1944. Start your Free Trial

What is Johnson & Johnson Cyclically Adjusted PB Ratio?

As of today (2025-06-30), Johnson & Johnson's current share price is $151.97. Johnson & Johnson's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $31.25. Johnson & Johnson's Cyclically Adjusted PB Ratio for today is 4.86.

The historical rank and industry rank for Johnson & Johnson's Cyclically Adjusted PB Ratio or its related term are showing as below:

JNJ' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 4.29   Med: 5.35   Max: 6.54
Current: 4.88

During the past years, Johnson & Johnson's highest Cyclically Adjusted PB Ratio was 6.54. The lowest was 4.29. And the median was 5.35.

JNJ's Cyclically Adjusted PB Ratio is ranked worse than
81.5% of 746 companies
in the Drug Manufacturers industry
Industry Median: 1.99 vs JNJ: 4.88

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Johnson & Johnson's adjusted book value per share data for the three months ended in Mar. 2025 was $32.469. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $31.25 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Johnson & Johnson Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Johnson & Johnson's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Johnson & Johnson Cyclically Adjusted PB Ratio Chart

Johnson & Johnson Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.98 6.07 5.89 5.12 4.69

Johnson & Johnson Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.11 4.72 5.24 4.69 5.31

Competitive Comparison of Johnson & Johnson's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, Johnson & Johnson's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Johnson & Johnson's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Johnson & Johnson's Cyclically Adjusted PB Ratio falls into.


;
;

Johnson & Johnson Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Johnson & Johnson's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=151.97/31.25
=4.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Johnson & Johnson's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Johnson & Johnson's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=32.469/134.9266*134.9266
=32.469

Current CPI (Mar. 2025) = 134.9266.

Johnson & Johnson Quarterly Data

Book Value per Share CPI Adj_Book
201506 25.689 100.684 34.426
201509 25.857 100.392 34.752
201512 25.824 99.792 34.916
201603 26.401 100.470 35.455
201606 26.473 101.688 35.126
201609 26.728 101.861 35.404
201612 26.018 101.863 34.463
201703 26.101 102.862 34.237
201706 26.785 103.349 34.969
201709 27.553 104.136 35.700
201712 22.427 104.011 29.093
201803 23.583 105.290 30.221
201806 23.446 106.317 29.755
201809 24.086 106.507 30.513
201812 22.444 105.998 28.569
201903 22.200 107.251 27.929
201906 23.007 108.070 28.725
201909 22.125 108.329 27.557
201912 22.591 108.420 28.114
202003 23.285 108.902 28.850
202006 23.924 108.767 29.678
202009 24.494 109.815 30.095
202012 24.037 109.897 29.512
202103 25.006 111.754 30.191
202106 26.436 114.631 31.116
202109 26.694 115.734 31.121
202112 28.157 117.630 32.297
202203 28.413 121.301 31.605
202206 29.044 125.017 31.346
202209 28.507 125.227 30.715
202212 29.386 125.222 31.663
202303 27.275 127.348 28.898
202306 28.924 128.729 30.317
202309 29.590 129.860 30.745
202312 28.572 129.419 29.788
202403 29.094 131.776 29.790
202406 29.723 132.554 30.255
202409 29.144 133.029 29.560
202412 29.702 133.157 30.097
202503 32.469 134.927 32.469

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Johnson & Johnson  (NYSE:JNJ) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Johnson & Johnson Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Johnson & Johnson's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Johnson & Johnson Business Description

Address
One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
Executives
Robert J Decker officer: Controller, CAO ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Timothy Schmid officer: EVP, WW Chair, MedTech ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Joseph J Wolk officer: Exec VP, CFO JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Mark A Weinberger director METLIFE, INC., 200 PARK AVENUE, NEW YORK NY 10166
Vanessa Broadhurst officer: EVP, Global Corp Aff. ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Jennifer L Taubert officer: EVP, WW Chair, Pharmaceuticals JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
William Hait officer: See Remarks ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Peter Fasolo officer: VP, Worldwide Human Resources JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Kathryn E Wengel officer: EVP, Chief GSC Officer JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
John C Reed officer: EVP, Pharmaceuticals R&D ONE JOHNSON & JOHNSON PLAZA, WHQ 2134, NEW BRUNSWICK NJ 08933
James D. Swanson officer: EVP, Chief Information Officer ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Paula A Johnson director 22 CHERRY HILL DRIVE, DANVERS MA 01923
Ashley Mcevoy officer: EVP, WW Chair, Medical Devices JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Thibaut Mongon officer: Exec VP, WW Chair, Consumer JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Elizabeth Forminard officer: Executive VP, General Counsel ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933